Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

PaperCitations, authors & open-access status

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 3,367 citations, 2019 year and green oa status.

3,367
Citations
2019
Year
green
OA Status

Related on ScholarIQ

Myung‐Ju Ahn
Author
Venceslau Hespanhol
Author
Ying Cheng
Author
Yi‐Long Wu
Author
Qing Zhou
Author
Kai Wang
Author
470M+ articles · free account